Back to Cell Types

JVM-3Homo sapiens (Human)Transformed cell line

Also known as: JVM3

🤖 AI SummaryBased on 9 publications

Quick Overview

JVM-3 is a human B-prolymphocytic leukemia cell line derived from peripheral blood.

Detailed Summary

JVM-3 is a human B-prolymphocytic leukemia cell line established from peripheral blood of a patient with B-prolymphocytic leukemia. It is characterized by specific genetic alterations, including mutations in the BRAF gene and other epigenetic regulatory genes. The cell line has been used in studies related to the molecular mechanisms of leukemia, including the analysis of gene mutations and their implications in disease progression. JVM-3 is also noted for its utility in research involving the identification of neo-epitopes and the study of immune responses in cancer. The cell line has been utilized in genomic studies to understand the role of specific mutations in cancer development and treatment response.

Research Applications

Genomic studies of mutations in leukemiaAnalysis of epigenetic regulatory genesIdentification of neo-epitopes for cancer immunotherapyStudy of immune responses in cancer

Key Characteristics

BRAF mutationsEpigenetic regulatory gene mutationsUtilized in cancer immunotherapy research

Generated on 6/16/2025

Basic Information

Database ID	CVCL_1320
Species	Homo sapiens (Human)
Tissue Source	Peripheral blood[UBERON:UBERON_0000178]

Donor Information

Age	73
Age Category	Adult
Sex	Male

Disease Information

Disease	B-cell prolymphocytic leukemia
Lineage	Lymphoid
Subtype	B-Cell Prolymphocytic Leukemia
OncoTree Code	BPLL

DepMap Information

Source Type	DSMZ
Source ID	ACH-000346_source

Known Sequence Variations

Type	Gene/Protein	Description	Zygosity	Note	Source
MutationSimple	BRAF	p.Lys601Asn (c.1803A>T)	Heterozygous	-	from parent cell line U266B1
MutationSimple	ARID1B	p.Pro1435Leu (c.4304C>T)	Heterozygous	-	Unknown, PubMed=29989027

Haplotype Information (STR Profile)

Short Tandem Repeat (STR) profile for cell line authentication.

Amelogenin

X,Y

CSF1PO

10,12

D13S317

13

D16S539

11,12

D18S51

13,16

D19S433

14

D21S11

29,31

D2S1338

21,23

D3S1358

16

D5S818

11

D7S820

10

D8S1179

15

FGA

24,26

Penta D

12,13

Penta E

14,16

TH01

9,9.3

TPOX

8,9

vWA

17,18,19

Gene Expression Profile

Gene expression levels and statistical distribution

Loading cohorts...

Full DepMap dataset with combined data across cell lines

Loading gene expression data...

Publications

Pan-cancer proteomic map of 949 human cell lines.";

Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.

Cancer Cell 40:835-849.e8(2022).

The LL-100 panel: 100 cell lines for blood cancer studies.";

MacLeod R.A.F., Nagel S., Steube K.G., Uphoff C.C., Drexler H.G.

Sci. Rep. 9:8218-8218(2019).

Next-generation characterization of the Cancer Cell Line Encyclopedia.

Sellers W.R.

Nature 569:503-508(2019).

An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.

Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.

Cancer Res. 79:1263-1273(2019).

Screening human cell lines for viral infections applying RNA-Seq data analysis.

Uphoff C.C., Pommerenke C., Denkmann S.A., Drexler H.G.

PLoS ONE 14:E0210404-E0210404(2019).

Profiling the B/T cell receptor repertoire of lymphocyte derived cell lines.

Yang H.H., Koeffler H.P.

BMC Cancer 18:940.1-940.13(2018).

New generation sequencing of targeted genes in the classical and the variant form of hairy cell leukemia highlights mutations in epigenetic regulation genes.

Troussard X.

Oncotarget 9:28866-28876(2018).

A landscape of pharmacogenomic interactions in cancer.";

Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.

Cell 166:740-754(2016).

TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.

Loewer M., Sahin U., Castle J.C.

Genome Med. 7:118.1-118.7(2015).

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.

Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.

Nature 483:603-607(2012).

Detection of EBV, HBV, HCV, HIV-1, HTLV-I and -II, and SMRV in human and other primate cell lines.

Uphoff C.C., Denkmann S.A., Steube K.G., Drexler H.G.

J. Biomed. Biotechnol. 2010:904767.1-904767.23(2010).

A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.

Haber D.A.

Cancer Res. 70:2158-2164(2010).

Signatures of mutation and selection in the cancer genome.";

Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.

Nature 463:893-898(2010).

The establishment of cell lines from chronic B cell leukaemias: evidence of leukaemic origin by karyotypic abnormalities and Ig gene rearrangement.

Vaz de Melo J., Foroni L., Brito-Babapulle V., Luzzatto L., Catovsky D.

Clin. Exp. Immunol. 73:23-28(1988).

Two new cell lines from B-prolymphocytic leukaemia: characterization by morphology, immunological markers, karyotype and Ig gene rearrangement.

Luzzatto L., Catovsky D.

Int. J. Cancer 38:531-538(1986).

The leukemia-lymphoma cell line factsbook.";

Drexler H.G.

(In book) ISBN 9780122219702; pp.1-733; Academic Press; London; United Kingdom (2001).